Cargando…
Symptom trajectories during chemotherapy in patients with non‐small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy
BACKGROUND: Lung cancer, mainly non‐small cell lung cancer (NSCLC), is one of the leading causes of death worldwide. Currently, chemotherapy is still the most significant treatment strategy for NSCLC. However, scant attention has been paid in previous studies to those patients who often experience v...
Autores principales: | Liu, Jinghao, Liu, Xingyu, Dong, Ming, Zhao, Honglin, Li, Mei, Zhang, Hongbing, Ji, Huihui, Shi, Yi, Cui, Yajie, Wu, Di, Chen, Gang, Chen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952786/ https://www.ncbi.nlm.nih.gov/pubmed/33496072 http://dx.doi.org/10.1111/1759-7714.13830 |
Ejemplares similares
-
Chemotherapy and quality of life in advanced NSCLC
por: Farrugia, D, et al.
Publicado: (2001) -
OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014) -
Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022) -
Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017) -
Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
por: Cheng, Yajie, et al.
Publicado: (2022)